GALMED PHARMACEUTICALS LTD. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
GALMED PHARMACEUTICALS LTD. (GLMD) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $4.70 million for the 6-month period ending 2026-06-30, per its 6-K filed 2026-09-02.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-09-02
- GALMED PHARMACEUTICALS LTD. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $1.40M, a 56.25% decline year-over-year.
- GALMED PHARMACEUTICALS LTD. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $1.90M, a 0.00% change year-over-year.
- GALMED PHARMACEUTICALS LTD. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was $3.20M.
- GALMED PHARMACEUTICALS LTD. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was $1.90M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.70M 6-K · filed 2026-09-02 | ||||
| 2025-12-31 | $1.40M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $3.30M derived: sum of 2 quarters · filed 2026-03-31 | $6.90M 20-F · filed 2026-03-31 | ||
| 2025-09-30 | $1.90M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-26 | $5.50M 6-K · filed 2025-11-26 | |||
| 2025-06-30 | $3.60M 6-K · filed 2026-09-02 | ||||
| 2024-12-31 | $3.20M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $5.10M derived: sum of 2 quarters · filed 2026-03-31 | $7.50M 20-F · filed 2026-03-31 | $8.00M 20-F · filed 2025-04-02 | |
| 2024-09-30 | $1.90M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-26 | $4.30M 6-K · filed 2025-11-26 | |||
| 2024-06-30 | $2.40M 6-K · filed 2025-08-28 | ||||
| 2023-12-31 | $10.30M 20-F · filed 2026-03-31 | $6.90M 20-F · filed 2024-04-04 | |||
| 2023-06-30 | $3.40M 6-K · filed 2024-08-28 | ||||
| 2022-12-31 | $17.90M 20-F · filed 2025-04-02 | -$17.90M 20-F · filed 2023-03-29 | |||
| 2022-06-30 | $9.90M 6-K · filed 2022-08-04 | ||||
| 2021-12-31 | $32.40M 20-F · filed 2024-04-04 | ||||
| 2020-12-31 | -$28.80M 20-F · filed 2023-03-29 | -$28.77M 20-F · filed 2021-03-18 | |||
| 2020-06-30 | -$5.53M 6-K · filed 2020-08-06 | -$11.59M 6-K · filed 2020-08-06 | |||
| 2020-03-31 | -$6.06M 6-K · filed 2020-08-06 | ||||
| 2019-12-31 | $20.50M 20-F · filed 2022-05-02 | -$20.46M 20-F · filed 2020-03-12 | |||
| 2019-06-30 | -$4.17M 6-K · filed 2020-08-06 | -$7.66M 6-K · filed 2020-08-06 | |||
| 2019-03-31 | -$3.49M 6-K · filed 2020-08-06 | ||||
| 2018-12-31 | -$9.86M 20-F · filed 2021-03-18 | ||||
| 2018-06-30 | -$2.69M 6-K · filed 2019-08-05 | -$5.19M 6-K · filed 2019-08-05 | |||
| 2018-03-31 | -$2.51M 6-K · filed 2019-08-05 | ||||
| 2017-12-31 | -$12.30M 20-F · filed 2020-03-12 | ||||
| 2017-06-30 | -$2.69M 6-K · filed 2018-08-02 | -$5.85M 6-K · filed 2018-08-02 | |||
| 2016-12-31 | -$16.95M 20-F · filed 2019-03-13 | ||||
| 2016-06-30 | -$4.31M 6-K · filed 2017-07-31 | -$8.29M 6-K · filed 2017-07-31 | |||
| 2015-12-31 | -$10.62M 20-F · filed 2018-03-13 | ||||
| 2015-06-30 | -$2.35M 6-K · filed 2017-06-23 | -$4.82M 6-K · filed 2017-06-23 | |||
| 2014-12-31 | -$9.10M 20-F · filed 2017-03-23 | ||||
| 2013-12-31 | -$17.48M 20-F · filed 2016-03-22 | ||||
| 2012-12-31 | -$3.15M 20-F · filed 2015-03-31 |